Aktis Oncology
Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3.
IPO closed 12 January 2026. [225Ac]Ac-AKY-1189 (Nectin-4) in US phase 1b; [225Ac]Ac-AKY-2519 (B7-H3) IND planned H1 2026 after diagnostic imaging and dosimetry studies; in-house cGMP radiopharmaceutical facility due H2 2026. Backed by large pharma investors.
Pages like this
not linked directly; found by shared links- TechnologyBispecific ADC
Shares Nectin-4, B7-H3, Bladder & urothelial cancer and the tag frontier.
- TechnologyADC payload neutralisers
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologyPhotothermal (plasmonic) nanoparticle ablation
Shares Prostate cancer and the tag frontier.
- TechnologyMagnetic nanoparticle hyperthermia
Shares Prostate cancer and the tag frontier.
- TechnologyTrained innate immunity
Shares Bladder & urothelial cancer and the tag frontier.
- CompanyGenerate:Biomedicines
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologyRadio-antibody & radio-ADC
Shares Targeted alpha therapy and the tag frontier.
- TechnologyRadioligand plus DNA-repair inhibitor combinations
Shares Targeted alpha therapy, Prostate cancer and the tag frontier.